title: Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.
abstract: Molecular chaperone-peptide complexes extracted from tumors (heat shock protein [HSP] vaccines) have been intensively studied in the preceding two decades, proving to be safe and effective in treating a number of malignant diseases. They offer personalized therapy and target a cross-section of antigens expressed in patients' tumors. Future advances may rely on understanding the molecular underpinnings of this approach to immunotherapy. One property common to HSP vaccines is the ability to stimulate antigen uptake by scavenger receptors on the antigen-presenting cell surface and trigger T-lymphocyte activation. HSPs can also induce signaling through Toll-Like receptors in a range of immune cells and this may mediate the effectiveness of vaccines.
authors: Molecular and Cellular Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA.
authors: Ayesha
authors: A
authors: Murshid
authors: Jianlin
authors: J
authors: Gong
authors: Mary Ann
authors: MA
authors: Stevenson
authors: Stuart K
authors: SK
authors: Calderwood
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D055808:Drug Discovery / Q000266:history / Q000639:trends; D006360:Heat-Shock Proteins / Q000008:administration & dosage* / Q000378:metabolism*; D049674:History, 21st Century; D006801:Humans; D018832:Molecular Chaperones / Q000008:administration & dosage / Q000378:metabolism
chemical_list: D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; D018832:Molecular Chaperones